share_log

Medtronic | 10-Q: Q2 2025 Earnings Report

Medtronic | 10-Q: Q2 2025 Earnings Report

美敦力 | 10-Q：2025財年二季報
美股SEC公告 ·  2024/11/27 05:18

Moomoo AI 已提取核心訊息

Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.
Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.
美敦力報告了2025財年第二季度的穩健業績，營業收入增長5%至84億美元，攤薄後每股收益增長46%至0.99美元。這一增長得益於大多數業務的強勁表現，尤其是在糖尿病（+12%）、神經科學（+7%）和心血管（+6%）領域。國際市場增長強勁，增長率爲8%，而美國營業收入增長3%。營業利潤增長19%，達到16億美元，稅率爲18.0%，相比去年同期的30.6%大幅下降。公司保持強勁的流動性，季度末現金及現金等價物爲14億美元，流動投資爲66億美元。在本季度，美敦力以平均價格86.26美元回購了290萬股股票。展望未來，管理層將繼續專注於創新和市場拓展，同時關注包括競爭壓力、地域發展和供應鏈約束等宏觀挑戰。公司強調了關鍵增長驅動因素的持續動能，包括MiniMed 780G胰島素泵系統、Inceptiv脊髓刺激器和Hugo機器人手術平台。
美敦力報告了2025財年第二季度的穩健業績，營業收入增長5%至84億美元，攤薄後每股收益增長46%至0.99美元。這一增長得益於大多數業務的強勁表現，尤其是在糖尿病（+12%）、神經科學（+7%）和心血管（+6%）領域。國際市場增長強勁，增長率爲8%，而美國營業收入增長3%。營業利潤增長19%，達到16億美元，稅率爲18.0%，相比去年同期的30.6%大幅下降。公司保持強勁的流動性，季度末現金及現金等價物爲14億美元，流動投資爲66億美元。在本季度，美敦力以平均價格86.26美元回購了290萬股股票。展望未來，管理層將繼續專注於創新和市場拓展，同時關注包括競爭壓力、地域發展和供應鏈約束等宏觀挑戰。公司強調了關鍵增長驅動因素的持續動能，包括MiniMed 780G胰島素泵系統、Inceptiv脊髓刺激器和Hugo機器人手術平台。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間